Rapport Therapeutics, Inc.
RAPP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$25.93
KIRA · Stoqly’s AI analyst, in plain words
- Rapport Therapeutics, Inc. lost $111M in fiscal 2025.
- Free cash flow was −$88.1M in fiscal 2025, — of revenue.
Market cap
$1.2B
P/E
—
Revenue
—
Net income
−$111M
Free cash flow
−$88.1M
Operating margin
—
Rapport Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$111M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rapport Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Rapport Therapeutics, Inc.
- CIK
- 0002012593
Rapport Therapeutics, Inc. · RAPP
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$34.8M | −$78.3M | −$111M |
| Diluted EPS | −$23.10 | −$3.78 | −$2.86 |
| Cash | |||
| Cash from operations | −$27.2M | −$64.8M | −$87.5M |
| Capital expenditure | $1.6M | $2.4M | $0.6M |
| Free cash flow | −$28.8M | −$67.2M | −$88.1M |
| Share count change | — | 1,277.2% | 87.7% |
| Debt and strength | |||
| Cash and short-term investments | $147M | $305M | $491M |
| Shareholders' equity | −$25.6M | $305M | $485M |
| Current ratio | 17.1x | 35.3x | 26.2x |
| Returns and quality | |||
| Return on equity | — | −56.0% | −28.2% |
| Return on tangible equity | — | −25.6% | −23.0% |
| Altman Z'' | 1.6 | 37.0 | 21.3 |
Insiders bought, 12 months
$1.7M
6 insiders
Insiders sold, 12 months
$47.2M
6 insiders
Of sales under plans
99%
$46.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rapport Therapeutics, Inc. · RAPP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.93 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0002012593). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.